Molecular analysis identified ABC and GCB subtypes, with the ABC subtype benefiting more from the new regimen. The ...

Grewal, MD, assistant professor at the Winship Cancer Institute at Emory University discusses the significant and concerning ...

AI transforms cancer treatment by personalizing care and enhancing patient-provider communication, revolutionizing how patients manage their health.

A groundbreaking study reveals promising efficacy and safety of 212Pb-DOTAMTATE for treating neuroendocrine tumors, paving the way for future trials.

Experts discuss the impact of dose escalation in treating neuroendocrine tumors, highlighting recent trials and collaborative research efforts for improved patient outcomes.

Daraxonrasib received FDA orphan drug designation for pancreatic cancer, targeting RAS mutations in pancreatic ductal ...

Combinations of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) are the accepted ...

A new analysis reveals unique symptom burdens and quality of life challenges in younger patients with neuroendocrine tumors, ...

A recent trial evaluates the impact of dostarlimab on ovarian cancer treatment, revealing modest benefits and no significant safety concerns with niraparib.

Marshall emphasizes the complexity of staying updated with various cancers and treatments, the diverse knowledge bases among ...

The FDA has granted fast track designation to JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC), for the ...

These cases illustrate scenarios where final pathology often reveals a higher risk of recurrence than anticipated, requiring ...